[Effect of Consupren, Carvedilol and BL-443 on the composition of lactate dehydrogenase in tissues of rats with cyclosporin nephropathy].
L-Lactate dehydrogenase pattern in tissues was determined by polyacrylamide gel electrophoresis adjusted to be more sensitive to LD1 and LD2. Three groups of rats (Wistar) were treated for 18 days with single oral daily doses of 45 mg consuprene/kg body weight to induce cyclosporine nephropathy. Two treated groups were further medicated either with carvedilol or BL-443 in single daily doses of 10 mg/kg b.w., unmedicated rats were given single i.p. daily doses of 1 ml saline. No significant difference in the LD(1-4) isoenzyme pattern in the liver between intact rats, rats with cyclosporine nephropathy, and rats with cyclosporine nephropathy medicated with carvedilol or BL-443 was found by F-test and t-test (p < 0.05). However, a significant difference in the LD(1-4) isoenzyme pattern in the myocardium between rats with cyclosporine nephropathy and intact rats was found. The present study reports the preliminary results of the effects of consupren on the LD(1-4) pattern in the muscle, spleen, and lung, as well as the effects of carvedilol and BL-443 in the tissues under the conditions of experimental cyclosporine nephropathy. The tissues with an increased risk of affection can be identified by evaluation of LD patterns that may become an additional tool to microscopic examination of the sample.
Salplachta
J
J
Ustav biochemie a biofyziky Fakulty veterinární hygieny a ekologie Veterinární farmaceutické univerzity, Brno. salplachtaj@vfu.cz
Strnadová
V
V
Csöllei
J
J
D018674:Adrenergic Antagonists / Q000627:therapeutic use*; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002219:Carbamates / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D016572:Cyclosporine / Q000633:toxicity*; D007166:Immunosuppressive Agents / Q000633:toxicity*; D007527:Isoenzymes / Q000032:analysis; D007674:Kidney Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000201:enzymology*; D007770:L-Lactate Dehydrogenase / Q000032:analysis*; D008099:Liver / Q000201:enzymology; D008168:Lung / Q000201:enzymology; D008297:Male; D018482:Muscle, Skeletal / Q000201:enzymology; D009206:Myocardium / Q000201:enzymology; D011412:Propanolamines / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D013154:Spleen / Q000201:enzymology
D018674:Adrenergic Antagonists; D000959:Antihypertensive Agents; C452080:BL443; D002219:Carbamates; D002227:Carbazoles; D007166:Immunosuppressive Agents; D007527:Isoenzymes; D011412:Propanolamines; D000077261:Carvedilol; D016572:Cyclosporine; D007770:L-Lactate Dehydrogenase
Ucinky preparátů Consuprenu, carvedilolu a BL-443 na tkánové slození laktátdehydrogenasy u potkanů s cyklosporinovou nefropatií.